drugset / Trial / NCT00041379

Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00041379 ↗

Phase 1/2 Unknown LifeTime Pharmaceuticals
Treatment

Summary

RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I/II trial to study the effectiveness of beta alethine in treating patients who have Waldenstrom's macroglobulinemia.

Timeline

Start
2002-03
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject ALETHINE Small molecule — Subcutaneous

Indications